Ampulla of Vater Carcinoma

News alerts, weekly reports and conference planners

BRAF V600E	Ampulla of Vater Carcinoma	BRAF V600E	Ampulla of Vater Carcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
No biomarker	Ampulla of Vater Carcinoma	No biomarker	Ampulla of Vater Carcinoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Ampulla of Vater Carcinoma	No biomarker	Ampulla of Vater Carcinoma	5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline 5-fluorouracil + leucovorin calcium Sensitive : A2	5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline 5-fluorouracil + leucovorin calcium Sensitive : A2
RET fusion	Ampulla of Vater Carcinoma	RET fusion	Ampulla of Vater Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
NTRK3 fusion	Ampulla of Vater Carcinoma	NTRK3 fusion	Ampulla of Vater Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Ampulla of Vater Carcinoma	NTRK2 fusion	Ampulla of Vater Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Ampulla of Vater Carcinoma	NTRK1 fusion	Ampulla of Vater Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Ampulla of Vater Carcinoma	NTRK1 fusion	Ampulla of Vater Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Ampulla of Vater Carcinoma	NTRK2 fusion	Ampulla of Vater Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Ampulla of Vater Carcinoma	NTRK3 fusion	Ampulla of Vater Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Ampulla of Vater Carcinoma	No biomarker	Ampulla of Vater Carcinoma	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2
KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
MUC2 negative	Ampulla of Vater Carcinoma	MUC2 negative	Ampulla of Vater Carcinoma	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3
KRT7 expression	Ampulla of Vater Carcinoma	KRT7 expression	Ampulla of Vater Carcinoma	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3
KRT7 expression	Ampulla of Vater Carcinoma	KRT7 expression	Ampulla of Vater Carcinoma	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : C3	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : C3
KRT7 expression + MUC1 expression	Ampulla of Vater Carcinoma	KRT7 expression + MUC1 expression	Ampulla of Vater Carcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials gemcitabine + albumin-bound paclitaxel Sensitive : C3	gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials gemcitabine + albumin-bound paclitaxel Sensitive : C3
HER-2 mutation + CDK6 mutation	Ampulla of Vater Carcinoma	HER-2 mutation + CDK6 mutation	Ampulla of Vater Carcinoma	palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab/hyaluronidase-oysk Sensitive: C3 – Early Trials palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab / hyaluronidase-oysk Sensitive : C3	palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab/hyaluronidase-oysk Sensitive: C3 – Early Trials palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab / hyaluronidase-oysk Sensitive : C3
BRAF D594G	Ampulla of Vater Carcinoma	BRAF D594G	Ampulla of Vater Carcinoma	binimetinib + encorafenib Sensitive: C3 – Early Trials binimetinib + encorafenib Sensitive : C3	binimetinib + encorafenib Sensitive: C3 – Early Trials binimetinib + encorafenib Sensitive : C3
MDM2 amplification	Ampulla of Vater Carcinoma	MDM2 amplification	Ampulla of Vater Carcinoma	BI 907828 Sensitive: C3 – Early Trials BI 907828 Sensitive : C3	BI 907828 Sensitive: C3 – Early Trials BI 907828 Sensitive : C3
PIK3CA mutation	Ampulla of Vater Carcinoma	PIK3CA mutation	Ampulla of Vater Carcinoma	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
NRAS mutation + BRAF mutation	Ampulla of Vater Carcinoma	NRAS mutation + BRAF mutation	Ampulla of Vater Carcinoma	MEK inhibitor Sensitive: C4 – Case Studies MEK inhibitor Sensitive : C4	MEK inhibitor Sensitive: C4 – Case Studies MEK inhibitor Sensitive : C4
HER-2 G660D + HER-2 S310F	Ampulla of Vater Carcinoma	HER-2 G660D + HER-2 S310F	Ampulla of Vater Carcinoma	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4

Ampulla of Vater Carcinoma

Associations(22)

Associations
(22)